CytoMed Therapeutics (NASDAQ:GDTC) Releases Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its quarterly earnings data on Wednesday. The company reported ($0.06) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Trading Down 5.2%

Shares of NASDAQ:GDTC opened at $0.84 on Thursday. The business’s 50 day simple moving average is $0.90 and its two-hundred day simple moving average is $0.98. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06. CytoMed Therapeutics has a 52-week low of $0.68 and a 52-week high of $3.68.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on GDTC shares. Fundamental Research set a $4.16 target price on shares of CytoMed Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.16.

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.